Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

• Published in: Hepatology (Baltimore, Md.) Vol. 75; no. 2; pp. 473 - 488
• Main Authors: Friedman, Scott L., Pinzani, Massimo
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2022
• Subjects: Animal models; Animals; Antifibrotic Agents; Artificial intelligence; Biomedical Research; Biopsy; Cell interactions; Clinical trials; Clinical Trials as Topic; Drug Development; Etiology; Fibrosis; Hepatitis; Hepatology; Humans; Learning algorithms; Liver; Liver - diagnostic imaging; Liver - pathology; Liver Cirrhosis - diagnostic imaging; Liver Cirrhosis - drug therapy; Liver Cirrhosis - etiology; Liver Cirrhosis - pathology; Machine learning; Molecular modelling; Needs Assessment

Steady progress over four decades toward understanding the pathogenesis and clinical consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet none has been approved. Thus, an assessment of the field is timely, to clarify priorities and accelerate progress. Her...